214 related articles for article (PubMed ID: 36300095)
1. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer.
Ding H; Zhang J; Zhang F; Xu Y; Yu Y; Liang W; Li Q
Front Oncol; 2022; 12():990877. PubMed ID: 36300095
[TBL] [Abstract][Full Text] [Related]
2. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival.
Melief CJM; Welters MJP; Vergote I; Kroep JR; Kenter GG; Ottevanger PB; Tjalma WAA; Denys H; van Poelgeest MIE; Nijman HW; Reyners AKL; Velu T; Goffin F; Lalisang RI; Loof NM; Boekestijn S; Krebber WJ; Hooftman L; Visscher S; Blumenstein BA; Stead RB; Gerritsen W; van der Burg SH
Sci Transl Med; 2020 Mar; 12(535):. PubMed ID: 32188726
[TBL] [Abstract][Full Text] [Related]
3. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.
Massarelli E; William W; Johnson F; Kies M; Ferrarotto R; Guo M; Feng L; Lee JJ; Tran H; Kim YU; Haymaker C; Bernatchez C; Curran M; Zecchini Barrese T; Rodriguez Canales J; Wistuba I; Li L; Wang J; van der Burg SH; Melief CJ; Glisson B
JAMA Oncol; 2019 Jan; 5(1):67-73. PubMed ID: 30267032
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic approaches for HPV-caused cervical cancer.
Fatemi SA; Seifi N; Rasekh S; Amiri S; Moezzi SMI; Bagheri A; Fathi S; Negahdaripour M
Adv Protein Chem Struct Biol; 2022; 129():51-90. PubMed ID: 35305725
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
Lee SJ; Yang A; Wu TC; Hung CF
J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
[TBL] [Abstract][Full Text] [Related]
6. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
[TBL] [Abstract][Full Text] [Related]
7. Cervical Cancer Immunotherapy: Facts and Hopes.
Ferrall L; Lin KY; Roden RBS; Hung CF; Wu TC
Clin Cancer Res; 2021 Sep; 27(18):4953-4973. PubMed ID: 33888488
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer therapies: Current challenges and future perspectives.
Burmeister CA; Khan SF; Schäfer G; Mbatani N; Adams T; Moodley J; Prince S
Tumour Virus Res; 2022 Jun; 13():200238. PubMed ID: 35460940
[TBL] [Abstract][Full Text] [Related]
9. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer.
Shibata T; Lieblong BJ; Sasagawa T; Nakagawa M
Cancer Treat Rev; 2019 Aug; 78():8-16. PubMed ID: 31302573
[TBL] [Abstract][Full Text] [Related]
10. Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model.
Alson D; Schuyler SC; Yan BX; Samimuthu K; Qiu JT
Front Immunol; 2020; 11():927. PubMed ID: 32547541
[TBL] [Abstract][Full Text] [Related]
11. Advances in immunotherapy for cervical cancer.
Grau-Bejar JF; Garcia-Duran C; Garcia-Illescas D; Mirallas O; Oaknin A
Ther Adv Med Oncol; 2023; 15():17588359231163836. PubMed ID: 37007635
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic human papillomavirus vaccines: current clinical trials and future directions.
Hung CF; Ma B; Monie A; Tsen SW; Wu TC
Expert Opin Biol Ther; 2008 Apr; 8(4):421-39. PubMed ID: 18352847
[TBL] [Abstract][Full Text] [Related]
13. Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer.
Polten R; Kutle I; Hachenberg J; Klapdor R; Morgan M; Schambach A
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612258
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
Borcoman E; Le Tourneau C
Ther Adv Med Oncol; 2017 Jun; 9(6):431-439. PubMed ID: 28607581
[TBL] [Abstract][Full Text] [Related]
15. The current status of immunotherapy for cervical cancer.
Orbegoso C; Murali K; Banerjee S
Rep Pract Oncol Radiother; 2018; 23(6):580-588. PubMed ID: 30534022
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors.
Damm O; Nocon M; Roll S; Vauth C; Willich S; Greiner W
GMS Health Technol Assess; 2009 Mar; 5():Doc04. PubMed ID: 21289891
[TBL] [Abstract][Full Text] [Related]
17. Knowledge, attitudes, and practices of Saudi physicians regarding cervical cancer and the human papilloma virus vaccine.
Almazrou S; Saddik B; Jradi H
J Infect Public Health; 2020 Apr; 13(4):584-590. PubMed ID: 31570271
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T
Rebucci-Peixoto M; Vienot A; Adotevi O; Jacquin M; Ghiringhelli F; de la Fouchardière C; You B; Maurina T; Kalbacher E; Bazan F; Meynard G; Clairet AL; Fagnoni-Legat C; Spehner L; Bouard A; Vernerey D; Meurisse A; Kim S; Borg C; Mansi L
Front Oncol; 2022; 12():957580. PubMed ID: 35928870
[TBL] [Abstract][Full Text] [Related]
19. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.
Brinkman JA; Caffrey AS; Muderspach LI; Roman LD; Kast WM
Eur J Gynaecol Oncol; 2005; 26(2):129-42. PubMed ID: 15857016
[TBL] [Abstract][Full Text] [Related]
20. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]